malt1 inhibitors treatment  (MedChemExpress)

Journal: Molecular Medicine Reports

Article Title: MALT1 inhibition by MI-2 suppresses epithelial-to-mesenchymal transition and fibrosis by inactivating the NF-κB pathway in high glucose-treated HK-2 cells

doi: 10.3892/mmr.2025.13712

Figure Lengend Snippet: Effects of different concentrations of glucose on fibrosis and MALT1 expression in HK-2 cells. (A) Comparison of the relative fluorescence intensity of α-SMA among the NC, LG and HG groups, between the NC and LG groups, between the NC and HG groups, and between the LG and HG groups. (B) Comparison of the protein expression levels of FN among the NC, LG and HG groups, between the NC and LG groups, between the NC and HG groups, and between the LG and HG groups; and comparison of the protein expression levels of collagen I among the NC, LG and HG groups, between the NC and LG groups, between the NC and HG groups, and between the LG and HG groups. (C) Comparison of the protein expression levels of MALT1 among the NC, LG and HG groups, between the NC and LG groups, between the NC and HG groups, and between the LG and HG groups. *P<0.05, **P<0.01, ***P<0.001; ns, not significant; n=3/group. MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; α-SMA, α-smooth muscle actin; NC, negative control; LG, low-concentration glucose; HG, high-concentration glucose; FN, fibronectin.

Article Snippet: MI-2 (MedChemExpress), a MALT1 inhibitor, was used to suppress the protease function of MALT1.

Techniques: Expressing, Comparison, Fluorescence, Translocation Assay, Negative Control, Concentration Assay

Journal: HemaSphere

Article Title: Loss of CYLD promotes splenic marginal zone lymphoma

doi: 10.1002/hem3.70098

Figure Lengend Snippet: MALT1‐mediated cleavage of CYLD induces migration through the CCR7 receptor. (A) Immunoblot analysis of CYLD and MALT1 expression in primary SMZL samples. For CYLD analysis we used an antibody that recognizes both the full length CYLD and a C‐terminal fragment of CYLD (CYLD‐Ct). B‐actin was used as a loading control. Representative picture of immunoblot analysis in 7 SMZL primary samples. (B) Quantification of MALT1 protein levels in patients with SMZL using the Image J software. Values are shown as the ratio of MALT1/B‐actin for each patient. (C) RT‐qPCR analysis of CCR7 mRNA expression in CYLD full length and CYLD cleaved subgroups. Values are shown as the mean ± SEM of relative mRNA levels. (D) Expression levels of the CCR7 chemokine receptor were determined in CYLD full length and CYLD cleaved subgroups using flow cytometry. Values are shown as the mean ± SEM of CD19 + /CCR7 + percentages. (E) RT‐qPCR analysis of MMP9 mRNA expression in CYLD full length and CYLD cleaved subgroups. Values are shown as the mean ± SEM of relative mRNA levels. (F) Tumor cells from three SMZL patients expressing full length CYLD were electroporated with the CRISPR/Cas9 system including control (CYLD full length + sgCtl) and CYLD‐targeted (CYLD full length + sgCyld) sgRNAs. RT‐qPCR was used to analyze CYLD , CCR7 , IL6 , ICAM1 , CD80 , and MMP9 mRNA expression in CYLD full length + sgCtl and CYLD full length + sgCyld groups. Values are shown as the mean ± SEM of relative mRNA levels. Data were normalized to mRNA expression of CYLD full length + sgCtl group. (G) Representative immunoblot analysis of CYLD expression in tumor cells of samples analyzed in (F) . (H) Transendothelial migration analysis of three CYLD full length and CYLD cleaved SMZL patient samples in the presence or absence of chemokines (CCL19 and CCL21) and after pre‐incubation with anti‐CCR7 antibody (CCR7 AB) or isotype control (IC). Values are shown as the mean ± SEM. (I) Immunoblot analysis of CYLD expression in three CYLD cleaved SMZL patients treated with DMSO (vehicle) or MALT1 inhibitor MI‐2 (1 μM) for 6 h. (J) RT‐qPCR analysis of CCR7 mRNA expression in three CYLD cleaved SMZL patients treated with DMSO (vehicle) or MALT1 inhibitor MI‐2 (1 μM) for 24 h. Values are shown as the mean ± SEM of relative mRNA levels. (K) Expression levels of the CCR7 chemokine receptor were determined in three CYLD cleaved SMZL patients treated with DMSO (vehicle) or MALT1 inhibitor MI‐2 (1 μM) for 24 h, using flow cytometry. Values are shown as the mean ± SEM of CD19 + /CCR7 + percentages. (L) Transendothelial migration analysis of three CYLD cleaved SMZL patients in the presence of CCL19 and CCL21 chemokines, after pre‐incubation with DMSO (vehicle) or MALT1 inhibitor MI‐2 (1 μM) for 6 h. Values are shown as the mean ± SEM. (M), (N) Proliferation analysis by Trypan blue exclusion assay (M) and MTT assay (N) of three CYLD cleaved SMZL patients treated with DMSO (vehicle) or MALT1 inhibitor MI‐2 (1 μM) for, 24, 48, and 72 h. Values are shown as the mean ± SEM. (C)–(N) Statistical differences were assessed by Student's t ‐test (* ,#,$ p < 0.05; ** p < 0.01).

Article Snippet: The BTK inhibitor ibrutinib was purchased from Selleckchem (#PCI‐32765) and the MALT1 inhibitor MI‐2 was purchased from MedChemExpress (#HY‐12276).

Techniques: Migration, Western Blot, Expressing, Control, Software, Quantitative RT-PCR, Flow Cytometry, CRISPR, Incubation, Trypan Blue Exclusion Assay, MTT Assay